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HFE2 (hemochromatosis type 2 gene) is highly expressed in
skeletal muscle and liver hepatocytes. Its encoded protein,
hemojuvelin (HJV), is a co-receptor for the bonemorphogenetic
proteins 2 and 4 (BMP2 and BMP4) and enhances the BMP-
induced hepcidin expression. Hepcidin is a central iron regula-
tory hormone predominantly secreted from hepatocytes. HJV
also binds neogenin, a membrane protein widely expressed in
many tissues. Neogenin is required for the processing and
release of HJV from cells. The role that neogenin plays in HJV
trafficking was investigated, using HepG2 cells, a human hepa-
toma cell line. Knockdown of endogenous neogenin markedly
suppressesHJV release but has no evident effect onHJV traffick-
ing to the plasmamembrane. The addition of a soluble neogenin
ectodomain to cells markedly inhibits HJV release, indicating
that the HJV shedding is not processed before trafficking to the
cell surface. At the plasma membrane it undergoes endocytosis
in a dynamin-independent but cholesterol-dependent manner.
The additional findings thatHJV release is coupled to lysosomal
degradation of neogenin and that cholesterol depletion by fili-
pin blocks both HJV endocytosis and HJV release suggest that
neogenin-mediated HJV release occurs after the HJV-neogenin
complex is internalized from the cell surface.
Iron is an essential nutrient for a variety of biochemical pro-
cesses. Iron uptake into the body via the intestines is controlled
primarily by hepcidin (1). Hepcidin, a central iron-regulatory
peptide hormone, is predominantly produced by hepatocytes,
circulates in blood, and is excreted in urine (1–5). Hepatic hep-
cidin expression is regulated by dietary or parenteral iron load-
ing, iron stores, erythropoietic activity, tissue hypoxia, and
inflammation (1). Hepcidin deficiency resulting from the pri-
marymutations in humanHFE (hemochromatosis gene),TFR2
(transferrin receptor 2 gene), hemochromatosis type 2 gene
(HFE2), or the hepcidin gene itself (HAMP) is the major cause
of hereditary hemochromatosis (6). This heterogeneous group
of inherited iron overload disorders has a wide range of clinical
severity.
HFE2 is a recently cloned gene in humans and encodes a
protein termed hemojuvelin (HJV)2 (7). Its ortholog in mice is
called repulsive guidance molecule c (RGMc) because it is the
third member of the RGM family to be cloned (7–10). RGMa
and RGMb are expressed primarily in the developing and adult
central nervous system, which do not overlap with HFE2
expression (8–10).
The importance of HJV in iron homeostasis has been dem-
onstrated by the observations that the homozygous or com-
pound heterozygousmutations ofHFE2 gene cause the type 2A
juvenile hemochromatosis, a particularly severe form of hered-
itary hemochromatosis (7, 11, 12). Disruption of both HFE2
alleles (Hjv/) in mice also causes a severe iron overload (5).
The marked suppression of hepatic hepcidin expression
detected in juvenile hemochromatosis patients with the HFE2
mutation as well as in theHjv/mice has implicated HJV as a
key upstream regulator of hepatic hepcidin expression (5, 7, 13).
In the liver, a recent study using lacZ as a marker indirectly
showed a selective expression of HJV in periportal hepatocytes
(5). The hepatocyte is, therefore, the principal site inwhichHJV
exerts its regulatory role on hepcidin expression.
Like the other two RGM family members (RGMa and
RGMb), HJV is a co-receptor for the bone morphogenetic pro-
teins 2 and 4 (BMP2 and BMP4). HJV enhances hepatic hepci-
din expression via the BMP signaling pathway (14). Neither
RGMa nor RGMb appears to play a role in the regulation of
hepcidin expression. BMPs are cytokines of the transforming
growth factor superfamily that exhibitmultiple roles in awide
variety of processes through different signaling pathways (15,
16). BMP signaling is initiated upon ligand binding to BMP
receptors, which leads to a sequential phosphorylation of
receptor-activated Smads (Smad1, Smad5, and Smad8). The
phosphorylated Smad1/5/8 form heteromeric complexes with
Smad4. Upon formation, the complex translocates from the
cytoplasm to the nucleus to regulate gene expression (17).
Recent findings showing that liver-specific disruption of Smad4* Thisworkwas supported, inwholeor inpart, byNational Institutes ofHealth
Grants DK080765 (to A.-S. Z.) and DK54488 (to C. A. E.). This work was also
supported by funds from Amgen (to A.-S. Z.). The costs of publication of
this article were defrayed in part by the payment of page charges. This
article must therefore be hereby marked “advertisement” in accordance
with 18 U.S.C. Section 1734 solely to indicate this fact.
1 To whom correspondence should be addressed: Dept. of Cell and Develop-
mental Biology L215, Oregon Health & Science University, 3181 SW Sam
Jackson Park Rd., Portland, OR 97239. Tel.: 503-494-5846; Fax: 503-494-
4253; E-mail: zhanga@ohsu.edu.
2 The abbreviations used are: HJV, hemojuvelin; BMP, bone morphogenetic
protein; CM, conditioned culturemedium; ER, endoplasmic reticulum; GPI,
glycosylphosphatidylinositol; PI-PLC, Phosphatidylinositol-specific
phospholipase C; RGM, repulsive guidance molecule; Tf, transferrin;
TGN, trans-Golgi network; MEM, minimum essential medium; siRNA,
small interfering RNA;MesNa, sodium2-mercaptoethanesulfonate; tTA, tet-
racycline transactivator.
THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 283, NO. 25, pp. 17494–17502, June 20, 2008
© 2008 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in the U.S.A.
17494 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 283•NUMBER 25•JUNE 20, 2008
 at CALIFO
RNIA INSTITUTE O
F TECHNO
LO
G
Y on June 23, 2008 
w
w
w
.jbc.org
D
ow
nloaded from
 
markedly decreases hepcidin expression and causes iron accu-
mulation in mice (18) also support the importance of BMP sig-
naling in iron homeostasis.
The regulation of HJV appears to be primarily at the post-
transcriptional level. HFE2 is expressed highly in both skeletal
and heart muscle and at lower levels in liver (7). HFE2 mRNA
levels do not vary with iron loading in the liver of mice or with
iron depletion in the skeletal muscle of rats (19, 20). The levels
of serumHJVdo increase in the early phase of iron deficiency in
rats (20). HJV is a GPI-anchored protein (21), and in vitro stud-
ies demonstrated that HJV undergoes active release (shedding)
from the HFE2-transfected cells as well as from the differenti-
ated C2 or C2C12 cells (mouse myoblast cell lines), which
robustly express endogenous HJV (20, 22, 23). In agreement
with the finding in iron-deficient rats, HJV release from the cell
lines is inhibited by iron-saturated Tf (holo-Tf) or non-Tf iron
salts (20, 22, 24, 25). The observations that no evident defect in
muscle development is observed in juvenile hemochromatosis
patients andHjv/mice rule out the possibility that HJV has a
primary role in muscle development (7, 11, 12). However, skel-
etal muscle, accounting for 35–40% of body weight, has the
highest expression of HFE2mRNA (7) and is also a significant
iron consumer for myoglobin synthesis with serumTf presum-
ably as its source of iron. The findings that soluble HJV plays a
critical role in the negative regulation of hepatic hepcidin
expression through BMP signaling in hepatocytes support the
idea that skeletal musclemay serve as a body iron sensor as well
as the major source of serum HJV to indirectly modulate
hepatic hepcidin expression by regulating the HJV release into
the circulation (20, 22, 26, 27).
HJV also binds neogenin, a receptor for RGMa and netrins
(28, 29). Neogenin is amembrane protein and widely expressed
in most tissues, including liver and skeletal muscle (30–34).
The interactions of neogeninwith RGMa and netrins are essen-
tial for neural development (35, 36).Our previous study showed
that the interaction with neogenin is required for HJV release
from muscle cells (20). The G320V mutation in HJV accounts
for approximately two-thirds of cases of type 2A juvenile hemo-
chromatosis. This mutation disrupts the interaction of HJV
with neogenin, blocks HJV release, and results in the decreased
HJV targeting to the cell surface and the retention of HJV in the
endoplasmic reticulum (ER) (7, 20, 21, 37). These findings
imply that neogeninmay play a critical role in HJV intracellular
trafficking. Howneogenin is involved in this process remains to
be elucidated.
In this study, we investigated the role of neogenin in HJV traf-
ficking inHepG2 cells.We found that knockdown of endogenous
neogenin markedly suppresses HJV release but has no evident
effect onHJV trafficking to the plasmamembrane. Release ofHJV
requires not only neogenin but also endocytosis presumably by a
cholesterol-sensitive and dynamin-independent pathway.
EXPERIMENTAL PROCEDURES
Cell Culture and Transfection—HepG2 cells were purchased
from ATCC and maintained in MEM, 10% fetal calf serum, 1
mM pyruvate, 1 nonessential amino acids (complete
medium). HepG2 cells stably expressing G320V (G320V-
HepG2) were generated using Nucleofector kit V (Amaxa Bio-
systems) as previously described (20). The G320V mutant
HFE2 cDNA was prepared as previously reported (21). HepG2
cells stably transfected with wild type HFE2 (HJV-HepG2) or
pcDNA3 empty vector (control-HepG2) were generated previ-
ously (20). The stably transfected cells weremaintained in com-
plete medium with 800 g/ml G418.
Knockdown of Endogenous Neogenin—Neogenin siRNA
(Dharmacon) was used to knock down the endogenous neoge-
nin in control and HJV-HepG2 cells as previously described
(20). RNAiMAX reagent (Invitrogen) was used for the transfec-
tion. The negative control siRNA was the same as previously
described (20). The cells were transfected with the siRNA twice
on days 1 and 3 tomaximize the efficacy of the knockdown.HJV
in cell lysates and the conditionedmedium (CM) and neogenin
in cell lysates were analyzed by Western blot.
Flow Cytometry Analysis—Flow cytometry analysis was used
to quantify the cell surface HJV in HJV-HepG2 cells with or
without neogenin knockdown. Briefly, the cells were first
detached from flasks with the cell dissociation buffer (Invitro-
gen). The cells were then incubatedwith affinity-purified rabbit
anti-HJV antibody (4 g/ml) in Hanks’ buffer supplemented
with 3% fetal bovine serum for 30min at 4 °C, followed by incu-
bation with phycoerythrin-conjugated goat anti-rabbit IgG
(1:500 dilution; Caltag, Burlingame, CA) in the same buffer for
30 min at 4 °C. Flow cytometry analysis was performed on a
Becton Dickinson FACSCalibur flow cytometer at the Core
Facility of OregonHealth & Science University. Rabbit IgG and
control-HepG2 cells were used as negative controls. The levels
of cell surfaceHJV are expressed as arbitrary units.We used the
standard deviation and the paired and two-tailed Student’s t
test to evaluate the statistical significance of the cell surfaceHJV
in HepG2 cells with or without neogenin knockdown.
Phosphatidylinositol-specific Phospholipase C (PI-PLC)
Cleavage of Cell Surface HJV—Approximately 106 HJV-HepG2
cells in 6-well plate were incubated in 0.5 ml of plain MEM in
presence or absence of PI-PLC (Molecular Probes) at the con-
centration of 1 unit/ml at 37 °C in 5% CO2 incubator or at 4 °C
for the time intervals indicated in the text. The supernatants
were collected, and the cell lysates were prepared using NET-
Triton buffer (150 mMNaCl, 5 mM EDTA, and 10 mM Tris (pH
7.4) with 1% Triton X-100) with 1 protease inhibitor mixture
(Roche Applied Science). Approximately one-third of the cell
lysates or supernatants was subjected to 11% SDS-PAGE, fol-
lowed by immunodetection of HJV and neogenin as described
under “Immunodetection.”
HJV Release—The effects of the ectodomain (extracellular
domain) of neogenin, bafilomycin A (an inhibitor of the vacu-
olar H-ATPase; Sigma), dynasore (a cell-permeable inhibitor
of dynamin; Sigma), and filipin (a cholesterol-binding agent;
Sigma) on HJV release from HJV-HepG2 cells were examined.
The ectodomain of neogenin was generated by subcloning the
neogenin cDNA encoding the hydrophobic signal sequence
(residues 1–33) and the ectodomain (residues 34–1103) with a
C-terminal His6 tag into the pVL1393 baculovirus transfer vec-
tor (BD Biosciences). The recombinant protein was purified
from the supernatant of baculovirus-infectedHigh 5 cells using
nickel-nitrilotriacetic acid and gel filtration chromatography.
HJV-HepG2 cells were cultured in the 12-well plates. After 48 h
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of incubation with 60% confluence, fresh MEM, 5% fetal calf
serum was changed with the addition of neogenin ectodomain
at 0, 250, 500, 750, and 1,000 nM and incubated for 24 h. HJV
in50%ofcell lysate and20%of theCMwasanalyzedbyWestern
blot. For the inhibitors, the experiments were conducted when
HJV-HepG2 cells were 80% confluence. The cells were incu-
bated in the absence or presence of bafilomycinA (100 nM), dyna-
sore (80 and 160 M), or filipin (1, 5, and 10 g/ml) for the indi-
cated time intervals where no evident cytotoxicity was detected.
The whole cell lysate and 50% of CMwere analyzed.
Expression of Wild Type and Mutant Dynamin—To block
dynamin-mediated endocytosis, adenoviruses were used to
infect cells to introduce wild type or K44A mutant dynamin-1
(dynamin) into HJV-HepG2 cells. The viruses were kindly pro-
vided by Dr. Sandra Schmid at the Scripps Research Institute
(La Jolla, CA). The viral infections were conducted as described
previously with some modifications (38). Briefly, HJV-HepG2
cells were subcultured into 12-well plates 24 h before the
infection. The cells were overlaid with 250 l of binding
medium (Hanks’ salts containing 1mMMgCl2, 1mMCaCl2, and
10 mM Hepes, pH 7.2) containing the mixture of tTA activator
virus andwild type orK44A-dynamin-1 virus at equal ratios. To
generate the cells with various levels of dynamin, different
amounts of viruswere added as indicated in the text. After 2 h of
incubation at 37 °C to enable viral attachment and infection,
binding medium was changed to complete medium. After 18 h
of incubation to allow the expression of introduced dynamin,
the medium was replaced with 600 l of fresh complete
medium. The cultured conditioned medium was collected to
assay HJV release after an additional 24 h of incubation. The
levels of dynamin in cell lysate were analyzed as described
under “Immunodetection.” In this study, cells infected with
tTA activator virus alone were served as negative controls.
HJV Internalization—The internalization of biotinylated cell
surface HJV was conducted as previously described (39–41).
Briefly, HJV or control HepG2 cells in 6-well plate at 80%
confluence were biotinylated with 0.25 mg/ml Sulfo-NHS-Bio-
tin (Pierce) at 4 °C for 20 min. The cells were then incubated at
37 °C for the time intervals indicated in the text. Biotin remain-
ing on cell surface was stripped using MesNa (Sigma) at 4 °C.
Alternatively, the cells were incubated in presence of PI-PLC (1
unit/ml) at 4 °C for 3 h to release the cell surface GPI-anchored
proteins. The cells were then solubilized in NET-Triton/1
protease inhibitors mixture, followed by using streptavidin-
agarose beads (Pierce) to isolate the biotinylated HJV (internal-
ized fraction). The total cell surface HJV was isolated with
strepavidin-agarose from biotinylated cells labeled at 4 °C.
125I-Tf Uptake—125I-Tf uptake was used to detect the effect
of dynasore and filipin onTfR1-mediated Tf uptake. The rate of
125I-Tf uptake was determined as described previously (42)
with the following modifications. HepG2 cells in 6-well plates
were first preincubated in 1 ml of uptake medium (MEM, 2
mg/ml ovalbumin, 20mMHepes, pH 7.2) with dynasore (80 and
160 M) or filipin (10 g/ml) for 30 min at 37 °C. 125Tf uptake
was then initiated by changing to the uptake medium contain-
ing 50 nM 125Tf as well as the same concentrations of dynasore
or filipin. The inclusion of 1mg/ml unlabeledTfwas used as the
control for nonspecific uptake. After an 8-min incubation at
37 °C, externally bound Tf was stripped by acid wash. The
radioactivity remaining within cells was counted. The amount
of specific uptake in the presence of inhibitors was expressed as
the percentage of corresponding controls. The standard devia-
tion and the paired and two-tailed Student’s t test were used to
evaluate the statistical significance between the groups with
and without inhibitors.
Immunodetection—Cell lysate protein and CM were sub-
jected to SDS-PAGE under reducing conditions, followed by
transfer onto nitrocellulose membrane. The membranes were
probed with affinity-purified rabbit anti-HJV antibody (0.22
g/ml), rabbit anti-neogenin antibody (0.4 g/ml; Santa Cruz
Biotechnology), mouse anti-dynamin (1:4000; Upstate), or
mouse anti--actin antibody (1:10,000; Chemicon Interna-
tional), followed by immunodetection using corresponding
horseradish peroxidase-conjugated secondary antibody
(Chemicon International, Temecula, CA). The bands were
exposed to x-ray film by chemiluminescence (Super Signal;
Pierce).
RESULTS
Knockdown of Endogenous Neogenin Has No Effect on HJV
Trafficking to the Plasma Membrane but Blocks HJV Release—
Our previous studies demonstrate that HJV interacts with neo-
genin in HEK293 cells and that interaction with neogenin is
required for HJV release in C2C12 cells, a mouse myoblast cell
line (20, 21). Recent studies indicate that the G320V mutant
form of HJV that does not bind neogenin remains predomi-
nantly in the ER and does not traffic efficiently to the plasma
membrane (21, 37). These observations suggest a critical role of
neogenin inHJV trafficking. To gain insight into the function of
neogenin in this process, we first examined its role in HJV traf-
ficking to the plasma membrane in HepG2 cells. HepG2 cells
are of a relatively well differentiated human hepatoma cell line
that expresses many hepatocyte-specific genes including Tf,
hepcidin,TfR2, and ceruloplasmin (data not shown). The endo-
genously expressed neogenin is readily detectable by Western
blot (Fig. 1A). We used siRNA to knock down the neogenin in
HepG2 cells stably transfected with HJV (HJV-HepG2) and
then quantified the levels of cell surface HJV by flow cytometry
analysis. In comparison with the control siRNA, siRNA specific
to human neogenin was able to eliminate detectable neogenin
(Fig. 1A). Flow cytometry analysis revealed a mild but not sta-
tistically significant increase (p 0.36) (Fig. 1C). Similar results
were obtained by immunofluorescent analysis of nonpermeabi-
lized cells (data not shown). To confirm the lack of change in
cell surfaceHJVwith the knockdownof neogenin, we examined
the amount of HJV released by PI-PLC, which cleaves the phos-
phodiester bond of GPI-linked proteins. Similar quantities of
HJV were released upon PI-PLC cleavage whether or not neo-
genin was present in the cells (Fig. 1A). Consistent with the
previous reports showing complex processing of HJV (21, 23),
three distinctHJVbandsmigrating at approximately 50, 33, and
15 kDa were detected in the supernatants of PI-PLC digestion
(Fig. 1A, bottom panel). Down-regulation of neogenin does not
alter this profile. Taken together, these results indicate that
neogenin is not required for HJV trafficking to the plasma
membrane.
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Because neogenin did not affect the biosynthetic pathway of
HJV, the effect of neogenin on the shedding of HJV was exam-
ined. Detection of HJV in the CM by Western blot analysis
revealed amarked decrease of releasedHJVwhen neogeninwas
depleted (Fig. 1B). The multiple HJV bands migrating at 37
kDa in the conditioned medium are in agreement with the pre-
vious observations (20, 23), implying the existence of multiple
cleavage sites (Fig. 1B). These results suggest that both myo-
cytes and hepatocytes share similar pathways of neogenin-me-
diated HJV release. Importantly, these results also imply that
neogenin influences the shedding of HJV after it traffics to the
cell surface.
Soluble Neogenin Inhibits HJV Release—Neogenin is a type I
transmembrane protein consisting of an extracellular ectodo-
main, a transmembrane domain, and a cytoplasmic domain
(33). The binding of neogenin to HJV has been mapped to the
ectodomain of neogenin with a binding affinity of 500 nM
(43). We used purified ectodomain of neogenin to competi-
tively disrupt the HJV-neogenin interaction at the cell surface
and then examined the effect of this disruption on HJV release.
In this study, we directly added ectodomain of neogenin to the
culture medium of HJV-HepG2 cells. After 24 h of incubation,
HJV in the cultured conditioned medium was analyzed by
Western blot. In comparisonwith the parallel controls showing
active HJV release, the dose response to neogenin ectodomain
indicates that inhibition of HJV release was achieved over a
similar concentration range as the binding affinity (Fig. 2, top
panel). A similar inhibition of HJV release was observed when
neogenin expression was knocked down using neogenin siRNA
(Fig. 1B). Endogenous neogenin levels increase slightly upon
treatment with the ectodomain fragment (Fig. 2, bottom panel),
indicating that the binding of soluble neogenin to HJV could
inhibit the down-regulation of endogenous neogenin by HJV.
Together with the neogenin knockdown studies, these results
indicate that the neogenin fragment competes with the endog-
enous neogenin for binding to HJV. The interaction of HJV
with full-length neogenin is essential for both the processing
and release of HJV as well as for the down-regulation of neoge-
nin after HJV reaches the cell surface.
HJV Release Is Correlated with Neogenin Degradation—We
observed that expression of HJV in HepG2 cells resulted in
lower levels of endogenous neogenin (20). To further evaluate
the role of HJV in the down-regulation of neogenin, we first
compared the effect of wild type andG320VHJV expression on
the level of neogenin. The G320Vmutant, which does not bind
neogenin, was used as a negative control. Wild type HJV, but
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B.  HJV release
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FIGURE 1.KnockdownofneogeninblocksHJV releasebutdoesnot affect
HJVcell surfaceexpression.WeusedsiRNAspecific tohumanneogeninand
Lipofectamine RNAiMax to knockdown the endogenous neogenin in control
and HJV-HepG2 cells as described under “Experimental Procedures.” Scram-
bled siRNA was used as a parallel negative control. A, cell-associated protein.
PI-PLC digestion was used to examine the effect of neogenin knockdown on
the dynamic HJV expression on cell surface. The cells from above were incu-
bated in the presence or absence of PI-PLC at the concentration of 1 unit/ml
for 2 h in 37 °C CO2 incubator. HJV, neogenin (neo), and actin in cell lysates (L)
and the HJV in supernatant (HJV (sup)) were detected by Western blot analy-
sis. B, HJV release. At 24 h after the second transfection of cells with siRNA, the
cellswerepooled and subcultured into 12-well plateswith completemedium
containing 10% fetal calf serum. Approximately 48 h later, 100 l of the CM
was subjected to SDS-PAGE and Western blot analysis for HJV (HJV (CM)).
C, flow cytometry analysis of the cell surface HJV. Flow cytometry analysis of
cell surface HJV was analyzed as described under “Experimental Procedures”
and expressed as arbitrary units (a.u.). The averages of four individual analy-
ses and the standard deviationswere presented. All of the other experiments
were repeated at least three times with consistent results.
C           0          250          500          750          1000   nM
HJV(CM)-
- 45 kD
HJV (L)-
actin (L)- - 45 kD
neo (L)- -206 kD
FIGURE 2. The ectodomain of neogenin blocks HJV release. HFE2 stably
transfected (HJV) and empty vector transfected control (C)-HepG2 cells in
12-well plate were incubated in the absence or presence of the soluble
ectodomain of neogenin at 0–1000 nM for 24 h. Approximate half of the cell
lysate (L) and 20% of the CM was subjected to Western blot analysis for HJV
and neogenin (neo). Actin was also probed in the lysate as a protein loading
control. The experiments were repeated three times with consistent results.
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not the G320V mutant, markedly decreased neogenin protein
levels and undergoes active release (Fig. 3A). A similar effect
obtained in at least three individual stably transfected clones for
each construct ruled out a clonal effect (data not shown). Alter-
natively, we used PI-PLC, which can release cell surface HJV
into the medium, to determine the effect of HJV on neogenin
levels. PI-PLC was directly added into the culture medium of
HepG2 cells expressing HJV or G320V HJV at 37 °C, and the
cells were incubated for 3 h. Under these conditions, PI-PLC is
expected to release HJV. If the full-length HJV-neogenin com-
plex is required for internalization and neogenin degradation,
treatment of HJV-HepG2 cells with PI-PLC should release HJV
from cell and elevate the cellular neogenin level. Consistent
with this hypothesis, PI-PLC released HJV and resulted in a
marked increase of neogenin after a 3-h incubation, as com-
pared with the corresponding controls with no PI-PLC (Fig.
3B). Importantly, an increase of neogenin was not detected in
the empty vector-transfected control or in G320V HepG2 cells
where the G320 HJV mutant is located mainly in the ER (Fig.
3B) or in HJV-HepG2 cells at 4 °C (data not shown). These
results suggest that HJV and neogenin internalize prior to neo-
genin degradation.
The increased neogenin degradation could result from the
following two possibilities, the release of HJV/neogenin as a
complex and/or the sorting to and degradation of neogenin in
lysosomes. No shed neogenin could be detected in the concen-
trated conditionedmedium fromHJV-HepG2 cells byWestern
blot analysis under conditions where cellular neogenin
decreased (data not shown). To determine whether neogenin is
degraded in lysosomes, we treated HJV-HepG2 cells with
bafilomycin A, an inhibitor of the vacuolar H-ATPase (44),
which dissipates the pH gradient in the intracellular organelles
and thereby blocks protein degradation in lysosomes. After a
4-h incubation with 100 nM bafilomycin A, a significant
increase of cellular neogenin in HJV-HepG2 cells was apparent
(Fig. 3C). Interestingly, HJV release does not seem to be altered.
These results suggest that lysosome is the site of neogenin deg-
radation and that HJV shedding does not depend on low pH. In
addition, themild increase of cellular HJV in presence of bafilo-
mycinA (Fig. 3C) also implies thatHJV releasemight not be the
sole pathway for cellular HJV turnover. Rather, a certain por-
tion ofHJVmay also be degraded in lysosomes. Taken together,
the above observations imply that the interaction of neogenin
with HJV triggers its internalization from plasma membrane
for either cleavage or lysosomal degradation.
HJV Release Is Inhibited by Cholesterol Depletion but Not by
Dynamin Inhibitors—Plasma membrane proteins can be inter-
nalized by at least four known pathways, three of which require
dynamin for fission of the invaginated vesicles from the plasma
membrane (45). To determine whether HJV release from cells
was dependent on its endocytosis, we examined whether the
disruption of dynamin function affects HJV release from HJV-
HepG2 cells. Initially, dynasore, a cell-permeable inhibitor spe-
cific for the dynamin GTPase (46), was used to inhibit endocy-
tosis. Unexpectedly, no evident effect was detected when cells
were incubated in the presence of dynasore at the recom-
mended concentrations (80 and 160 M) (Fig. 4A). To test
whether these cells were sensitive to dynasore, the effect of
A.       C        HJV    G320V
neo (L)
actin (L)
HJV (CM)
HJV (L)
B.          C         HJV     G320V
       -     +    -     +      -     +
neo (L)
HJV (L)
PI-PLC
HJV (sup)
C.
Baf    -       +        -        +
  C              HJV
neo (L)-
HJV (L)-
actin (L)-
HJV (CM)-
-206 kD
-45 kD
-45 kD
-206 kD
-45 kD
-45 kD
-45 kD
-45 kD
-31 kD
-31 kD
FIGURE 3.HJV release is correlatedwith neogenindegradation.A, expres-
sion of HJV, but not G320Vmutant, decreases the level of neogenin protein in
HepG2 cells. Cell lysate from 2  105 cells and CM from 0.8  105 cells of
overnight culture were subjected to SDS-PAGE, followed by immunodetec-
tion of the HJV in both cell lysates (HJV (L)) and CM (HJV (CM)), and neogenin
(neo (L)) and actin in the lysate. B, PI-PLC digestions. HJV, G320V, and control-
HepG2 cells in 12-well plates at approximate 70%confluencewere incubated
in 300 l of MEM with or without the addition of PI-PLC (1 unit/ml) for 3 h at
37 °CCO2 incubator. Approximately half of the cell lysate or supernatantwere
subjected to SDS-PAGE, followed by immunodetection of HJV in both cell
lysate (L) and supernatant (sup), and neogenin (neo) and actin in the lysate.
C, bafilomycin A increases cellular neogenin. Control (C) and HJV-HepG2 cells
in 12-well plate were incubated for 4 h in complete medium with or without
the addition of 100 nM bafilomycin A (Baf). Neogenin, HJV, and actin in cell
lysate (L) and HJV in approximately one-third of CM were detected by West-
ernblot using the specific antibodies. All of the experimentswere repeated at
least three times with consistent results.
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dynasore on 125I-Tf uptake was measured because transferrin
receptor-mediated Tf uptake is a dynamin-dependent process.
Consistent with the previous observations (46), dynasore sig-
nificantly inhibited and completely blocks 125Tf internalization
at 80 and 160 M, respectively (Fig. 4B). These results suggest
that HJV release is independent of dynamin.
To further substantiate this observation, we next examined
the effects of the K44A mutant dynamin. The K44A mutation
disrupts the dynamin GTPase activity. It is widely used as a
dominant-negative to block the dynamin-dependent endocyto-
sis (38). HJV-HepG2 cells were infectedwith four different con-
centrations of adenovirus encoding either wild type or K44A
mutant dynamin. Consistent with the dynasore results, no evi-
dent inhibition of HJV release was detected when cells were
infected with the virus encoding the K44A dynamin mutant
(Fig. 4C). These results again support that dynamin-dependent
endocytosis is not involved in HJV release.
HJV is a GPI-anchored protein (21). Depletion of cholesterol
by filipin, a sterol-binding agent that binds to cholesterol, dis-
rupts both the endocytosis and exocytosis of GPI-anchored
proteins (45, 47–49). Therefore, we examined the effect of fili-
pin on HJV release from HJV-HepG2 cells. Filipin was added
directly to the culture medium at the concentrations ranging
from 0 to 10 g/ml. The cells were incubated for 2 h at 37 °C. A
marked decrease of HJV in the conditioned medium was evi-
dent in the presence of 10 g/ml of filipin (Fig. 4D). Longer
periods of incubation were not pursued because of the cytotox-
icity of filipin. Alternatively, the effects of filipin on the release
of biotinylated HJV were measured. Consistent with the above
finding, filipin was also found to markedly suppress the release
of HJV, which was derived from the cell surface (Fig. 4E). Fur-
ther analysis revealed that filipin does not significantly alter the
125Tf internalization compared with the control (p  0.4997)
(Fig. 4B). The relatively large variability in Tf uptake may result
from the effect of cholesterol depletion on clathrin-coated pit
internalization. Previous studies showed that the acute choles-
terol depletion markedly reduces the rate of internalization of
TfR1 by more than 85% (50). These results suggest that HJV
release depends on cholesterol and possibly on cholesterol-de-
pendent HJV endocytosis.
Endocytosis of Hemojuvelin—To elucidate whether cell sur-
face HJV undergoes endocytosis, cell surface proteins were
labeled at 4 °C with a cleavable form of biotin. Less than 10% of
the total HJV was biotinylated, suggesting that the majority of
HJV is localized intracellularly (Fig. 5A). To detect internalized
HJV, the cells were warmed to 37 °C for 10 min. Any biotin
remaining on cell surface was stripped by the nonpermeable
reducing agent,MesNa. The internalizedHJVwas then isolated
using streptavidin-agarose beads. Controls showed thatMesNa
could strip most of the biotin coupled to HJV in HJV-HepG2
cells left at 4 °C (Fig. 5A). Internalization was a rapid process.
The internalized HJV was detectable by Western blot after 5
min of incubation and reaches a plateau after 10min of incuba-
tion (Fig. 5A and data not shown). Similar results were also
obtained by using PI-PLC to strip the cell surface HJV (data not
shown). These findings indicate that HJV undergoes endocyto-
sis in HepG2 cells.
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FIGURE 4. Depletion of cholesterol inhibits HJV release. A, dynasore does
not inhibit HJV release. HJV-HepG2 cells in 12-well plates were incubated in
the presence of 0, 80, and 160M of dynasore for 2 h at 37 °C. HJV in both cell
lysate (L) and 50% of CM was detected by Western blot. B, 125I-Tf-uptake.
HepG2 cells in 6-well plates with approximate 80% confluencewere first pre-
incubated in absence or presence of dynasore (80 and 160M;D80 andD160,
respectively) and filipin (10 g/ml) (F) for 30 min at 37 °C. 125I-Tf uptake was
initiated by incubating the cells in the presence of 50 nM 125I-Tf and the same
concentrations of inhibitors. After 8 min of incubation at 37 °C, membrane-
bound 125I-Tf was removed by acid wash. The 125I radioactivity was counted.
The inclusion of 1 mg/ml unlabeled cold Tf was used as the nonspecific
uptake control. The rates of specific uptake in the presence of inhibitors were
expressed as the percentage of the corresponding controls. The results are
from four individual experiments. *, p  0.0281; **, p  0.0001. C, wild type
and K44A mutant dynamin. HJV-HepG2 cells in 12-well plates were infected
with the mixture of tTA activator virus and different amounts of adenovirus
containing either wild type or K44A mutant dynamin (0, 0.048, 0.096, 0.19,
and 0.38 l of stock virus/well). tTA activator virus alone was used as a nega-
tive control. The cellswere first incubated for18h to allow the expressionof
introduced dynamin. Afterward,20% of the CM collected from the incuba-
tion between 18 and 42 h post-infection was detected for HJV by Western
blot. In addition, dynamin (dyn), HJV, and actin in the cell lysate (L) at 42 h
post-infection were also analyzed. D, filipin inhibits HJV release. HJV-HepG2
cells in 12-well plates were incubated in the presence of 0, 1, 5, and 10g/ml
of filipin for 2 h at 37 °C. HJV inboth cell lysate (L) and50%ofCMwasdetected
byWestern blot. E, filipin inhibits the biotinylated cell surfaceHJV release. Cell
surface proteins in HJV-HepG2 cells were biotinylated at 4 °C, followed by
incubation in the presence of 0, 10, and 20g/ml of filipin at 37 °C for 2 h. The
biotinylated HJV that was released into themedium (HJV (CM)), as well as the
total biotinylated cell surfaceHJV (T) (HJV (S)), was isolatedusing streptavidin-
agarose beads and subjected to Western blot (lower panel). The total HJV in
cell lysate (L) was also detected (upper panel). All of the experiments were
repeated at least three times with consistent results. In each experiment, the
lysate and CM from control-HepG2 cells (C) were included as a negative con-
trol for HJV.
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HJV Endocytosis Is via Dynamin-independent but Possibly
Cholesterol-dependent Pathway—To further characterize the
pathway of HJV endocytosis, we examined the effect of filipin
and dynasore on the internalization of biotinylated cell surface
HJV in HJV-HepG2 cells. HJV internalization was markedly
inhibitedwhen cells were incubated in the presence of 10g/ml
filipin (Fig. 5B). However, no evident inhibition was detected
when cells were incubated in the presence of dynasore at con-
centrations of 80 and 160 M (Fig. 5B; data not shown). These
results suggest that HJV endocytosis is via the dynamin-inde-
pendent and cholesterol-dependent pathway, although the
definitive role of cholesterol in this process still remains to be
further characterized by other strategies.
DISCUSSION
The role of neogenin in HJV trafficking in HepG2 cells was
investigated. Our results show that knockdown of endogenous
neogenin markedly suppresses HJV release but has no evident
effect onHJV trafficking to the plasmamembrane. Themarked
inhibition of HJV release by soluble neogenin suggests that the
neogenin-regulated HJV release occurs after HJV traffics to the
plasma membrane. Furthermore, our data also indicate that
HJV shedding occurs after HJV is internalized.
HJV is a GPI-anchored protein (21) and, like other GPI-
linked proteins, is co-translationally translocated into the ER
where they are linked to a GPI anchor before trafficking to the
cell surface (51). In this study, we excluded the possibility that
HJV release occurs in its biosynthetic pathway. The observation
that neogenin knockdown does not alter the HJV trafficking to
the cell surface but does block the HJV release supports this
assumption. In addition, these findings also have an important
implicationwith respect to the possible defects ofG320Vmuta-
tion in HJV. The G320V mutation is the most frequently
detected mutation in type 2A juvenile hemochromatosis,
accounting for approximately two-thirds of cases (7). G320V
mutation abolishes the HJV-induced hepcidin expression (14).
Early studies demonstrated that it disrupts the interaction of
HJV with neogenin and that G320V mutant HJV has a
decreased targeting onto cell surface, is slightly shed, and is
largely retained in the ER (7, 20, 21, 23, 37).3 Because neogenin
is not required forHJV trafficking to the plasmamembrane, the
primary defect of the G320V mutation appears to be misfold-
ing, which consequently blocks its exit from the ER, the subse-
quent trafficking to the plasmamembrane, as well as lack of the
interaction with neogenin.
HJV release takes place after it traffics to the plasma mem-
brane and binds neogenin. The finding that HJV can efficiently
traffic to the plasma membrane in the absence of neogenin but
does not undergo release rules out the possibility that neogenin
acts as a chaperone to traffic HJV to the cell surface. Rather, the
association with neogenin is a prerequisite for shedding,
because soluble neogenin ectodomain can competitively inhibit
HJV release, similar to neogenin knockdown. The finding that
the addition of soluble neogenin ectodomain does not result in
the depletion of endogenously expressed neogenin in cells but
rather a slight increase in endogenous neogenin suggests that
the inhibition ofHJV release is caused by competitively disrupt-
ing the interaction of HJV with endogenous neogenin. These
observations therefore implicate a critical role of neogenin
transmembrane and cytoplasmic domains in the process of
HJV release.
Recent studies indicate that the HJV cleavage is mediated by
the proprotein convertase furin (24, 25). Furin is predominantly
localized in the TGN and cycles between the TGN and the
plasma membrane (52). Like transmembrane proteins, furin is
synthesized in the ER, and like other pro-enzymes, it is acti-
vated until it reaches its destination, which is the TGN in the
case of furin (52). This specific localization of furin and its traf-
ficking between the plasma membrane and the TGN and our
data, therefore, do not favor the findings in a recent report
stating that the furin-mediated HJV shedding occurs in the ER
(25). On the basis of our results, the endocytic compartments
are most likely the sites of HJV shedding. First, HJV release is
coupled to the increased neogenin degradation in lysosome.
Second, HJV undergoes endocytosis, and blockage of HJV
internalization inhibits HJV release.
Previous studies indicate that the endocytosis of many
GPI-anchored proteins is through dynamin-independent
but cholesterol-dependent pathway, because GPI-anchored
proteins are present at the surface in cholesterol-dependent
nanoscale clusters (45, 47–49). Our results showing that
cholesterol inhibitor, but not dynamin inhibitor, is able to
decrease HJV internalization tend to support that the endo-
cytosis of HJV follows this pathway. These observations also
imply that HJV endocytosis may depend on its GPI anchor.
However, this does not exclude other possibilities because
neogenin seems to play the critical role in this process. Neo-
genin has a cytoplasmic domain of 388 amino acids (33). The
role of neogenin cytoplasmic domain in this process remains
to be determined.
3 A.-S. Zhang and C. A. Enns, unpublished observations.
A.
B. -
-
-
0
+
-
-
0
+
-
-
10
+
+
-
10
+
-
+
10
MesNa
filipin
dynas
min
lysate          cs        intrnlzd
C    HJV     C   HJV    0'   10'
HJV-
HJV-
-45 kD
-45 kD
FIGURE 5.HJVundergoes endocytosis.A, internalization of biotinylated cell
surface HJV. Cell surface proteins in control (C) and HJV-HepG2 cells were
biotinylated at 4 °C, followed by incubation at 37 °C for 0 and 10 min (0 and
10). After stripping the biotin remaining on cell surface, the internalized HJV
(intrnlzd) was isolated using streptavidin-agarose beads and subjected to
Western blot. Approximately 10% of lysate from the cells without biotinyla-
tion (lysate) and the total biotinylated cell surface HJV without incubation
and stripping (cs) were included for the analysis. B, filipin inhibits HJV inter-
nalization. The experiments were conducted essentially the same as
described in A, except that the biotinylated cells were first preincubated in
the absence or presence of 10g/ml filipin or 160Mdynasore (dynas) at 4 °C
for 30 min before the incubation at 37 °C.
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On the basis of our data, we propose a model for the neoge-
nin-required and furin-mediated HJV shedding. The associa-
tion of HJV with neogenin on plasma membrane triggers the
internalization of both proteins as a complex. The complex is
then retrieved into a compartment, in which HJV is exposed to
furin for cleavage and the subsequent release, whereas neoge-
nin is sorted for degradation in lysosome. The fraction of HJV
that is unable to associate with neogenin would be targeted for
degradation.
Soluble HJV plays a critical role in the inhibition of hepatic
hepcidin expression through the BMP signaling (22, 24, 26, 27).
Studies in transfected cells indicate that holo-Tf and/or non-Tf
iron inhibits the shedding of HJV (20, 22, 37). Animal studies
suggest that serum HJV could be derived from both skeletal
muscle and liver hepatocytes (20). These observations, there-
fore, support that serum HJV plays a critical role in the regula-
tion of iron homeostasis. The findings in the present study
showing that soluble neogenin competitively blocks HJV
release and HJV release requires HJV endocytosis imply that
the regulation of HJV release by holo-Tf might take place at the
cell surface, after internalization or during the retrograde trans-
port. Thus holo-Tf would disrupt HJV-neogenin complex sim-
ilar to soluble neogenin and thereby modulate HJV release.
However, themechanism bywhich holo-Tf interferes withHJV
release still remains to be elucidated.
In summary, this study demonstrates that neogenin is not
required for HJV trafficking from the ER to the plasma mem-
brane, but the HJV-neogenin interaction at the cell surface is
essential forHJV release. Togetherwith the specific localization
of furin, the findings that HJV endocytosis is required for its
release suggest that neogenin-dependent retrograde trafficking
of HJV to furin positive compartments is necessary for HJV
shedding. How this process is regulated by iron still remains to
be explored and will be the subject of future research.
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